Draft:KVK-Tech
 | Review waiting, please be patient.
This may take 2–3 weeks or more, since drafts are reviewed in no specific order. There are 396 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2004 |
Area served | International |
| Products | Pharmaceutical |
| Services | Drug development and manufacturing |
| Website | www |
KVK-Tech, Inc. is a pharmaceutical company based in Newtown, Pennsylvania. The company develops and manufactures generic and branded pharmaceutical products, primarily in oral solid dosage form.
History
[edit]KVK-Tech was founded in 2004. The company produces generic medications for a variety of conditions, including hypertension, diabetes, and attention-deficit/hyperactivity disorder (ADHD). In 2016, the FDA approved Lomaira (phentermine hydrochloride tablets USP, 8 mg), a low-dose formulation of phentermine for weight management in adults with a body mass index (BMI) of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related comorbidity such as hypertension or type 2 diabetes.[1] In 2023, the company announced that Lomaira had been registered for sale in Mexico through a partnership with Medix.[2]
In 2024, KVK-Tech stated that it had expanded its research and development (R&D) facilities to support the development of complex generics and drug delivery technologies.[3]
Facilities and expansion
[edit]In 2023, KVK-Tech acquired a 200,000-square-foot facility in Newtown, Pennsylvania, previously operated by Lockheed Martin to increase manufacturing capacity and support additional research and development activities.[4][5]
In 2024, the company announced a distribution agreement to introduce its products to the Canadian market.
Partnerships
[edit]In 2023, the company partnered with Sen-Jam Pharmaceutical to develop and distribute pharmaceutical products related to pain and inflammation.[6]
Community programs
[edit]Since 2017, KVK-Tech has collaborated with the Council Rock School District in Bucks County, Pennsylvania, on science, technology, engineering, and mathematics (STEM) education programs.[7] In 2024, the company began offering scholarships to local students pursuing STEM-related fields.[8]
References
[edit]- ^ https://www.bizjournals.com/philadelphia/news/2016/09/21/fda-approves-lomaira-kvk-tech-weight-loss-pill.html
- ^ "KVK Tech's Lomaira has successfully completed registration in Mexico through its partner Medix" (Press release).
- ^ https://www.pharmaceuticalcommerce.com/view/kvk-tech-bolsters-r-d-to-tackle-complex-generics
- ^ "KVK-Tech Signs Agreement of Sale to Acquire Lockheed-Martin Facility in Newtown, PA | Fierce Pharma". 5 March 2015.
- ^ "Generic drugmaker snaps up Lockheed site with big expansion plans | Fierce Pharma". 5 March 2015.
- ^ "Sen-Jam Pharmaceutical Enters Strategic Partnership with KVK-Tech". 10 April 2024.
- ^ "BUILDING COGNITIVE CONNECTIONS: Newtown-based KVK Tech Inc. Partners with Council Rock to develop the next generation of scientists". May 2017.
- ^ https://www.buckscountycouriertimes.com/story/news/2024/09/20/kvk-tech-scholarships-stem-students/75234567007/